Menu
  • Join
  • Login
  • Contact
 

Search abstracts


Development of PEGylated aspartic acid modified liposome as a bone-targeting carrier for the delivery of paclitaxel and treatment of bone metastasis

  • At: 2017 FIP Congress in Stockholm (Sweden)
  • Type: Poster
  • By: YAMASHITA, Shugo (Kyoto Pharmaceutical University, Biopharmaceutics, Kyoto, Japan)
  • Co-author(s): Shugo Yamashita: Biopharmaceutics, Kyoto Pharmaceutical University, Kyoto, Japan
    Hidemasa Katsumi: Biopharmaceutics, Kyoto Pharmaceutical University, Kyoto, Japan
    Nozomi Hibino: Biopharmaceutics, Kyoto Pharmaceutical University, Kyoto, Japan
    Yugo Isobe: Biopharmaceutics, Kyoto Pharmaceutical University, Kyoto, Japan
    Yumiko Yagi: Biopharmaceutics, Kyoto Pharmaceutical University, Kyoto, Japan
    Yuka Tanaka: Biopharmaceutics, Kyoto Pharmaceutical University, Kyoto, Japan
    Saki Yamada: Biopharmaceutics, Kyoto Pharmaceutical University, Kyoto, Japan
    Kosuke Kusamori: Biopharmaceutics, Kyoto Pharmaceutical University, Kyoto, Japan
    Toshiyasu Sakane: Biopharmaceutics, Kyoto Pharmaceutical University, Kyoto, Japan
    Akira Yamamoto: Biopharmaceutics, Kyoto Pharmaceutical University, Kyoto, Japan
  • Abstract:

    Backgrounds

    The number of bone metastasis patients has been rapidly increasing in association with the global population aging. However, most anticancer drugs do not have a high affinity for bone hydroxyapatite under physiological conditions. Therefore, development of bone targeting system is highly required for the treatment of bone metastasis. In ..

  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 4 October 2019

FIP Congresses